Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc. discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft and Caleb Finch in 1996 and is headquartered in Charlottesville, VA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Acumen Pharmaceuticals reports robust Q4 earnings, ACU193 progress promising

Acumen Pharmaceuticals showcased strong financials and progress with ACU193 in their Q4 2022 earnings call. While facing challenges related to dosing strategies and commercial implications, the company is well-positioned to capitalize on opportunities for further development and market success.

Acumen Pharmaceuticals reports robust Q1 performance and advances Alzheimer's program

Acumen Pharmaceuticals demonstrates strong financial stability and progress in their Alzheimer's program.
Strategic focus on target engagement and dose selection enhances the clinical development pathway for ACU193.
Challenges lie in managing trial scenarios, but opportunities exist in data insights and regulatory interactions.

Acumen Pharmaceuticals reports positive Phase I results and solid financial standing

Acumen Pharmaceuticals showcased promising results for ACU193 in early Alzheimer's treatment and maintained a strong financial position with ample runway for future activities.
While facing challenges in dose selection and fundraising needs, the company has opportunities to advance drug development and explore innovative dosing methods.

Acumen Pharmaceuticals reports Q3 loss but advances Alzheimer's treatment

Acumen Pharmaceuticals showcased positive advancements in ACU193 with promising CSF biomarker results, despite reporting a loss from operations in Q3.
The company's strong financial position, highlighted by $282.7 million in cash and a new credit facility, supports ongoing research and development efforts.
Addressing operational challenges and seizing opportunities in refining treatment approaches and study timelines are crucial for Acumen Pharmaceuticals' future success.

Acumen Pharmaceuticals reports positive Phase I results for Alzheimer's treatment

Acumen Pharmaceuticals showcased progress in sabirnetug development, facing challenges in study design and dosing strategies while aiming to capitalize on therapeutic opportunities for Alzheimer's treatment.

Acumen Pharmaceuticals reports Q1 loss, progresses ALTITUDE study

Acumen Pharmaceuticals faces challenges in R&D expenses and logistical integration but shows strength in collaborations and enrollment progress.
Opportunities lie in diversification through new studies and potential incorporation of formulations into ongoing trials.
Overall, the company's financials and strategic focus indicate progress and commitment to advancing drug development.

Acumen Pharmaceuticals advances Alzheimer's treatment with strong financial backing

Acumen Pharmaceuticals is on track with the development of sabirnetug, backed by strong financials and a clear strategy to address Alzheimer's disease. While facing enrollment and market challenges, the company's upcoming R&D Day could unlock new opportunities for growth and innovation.

Acumen Pharmaceuticals reports progress in Alzheimer's treatment development and financial stability

Acumen Pharmaceuticals is making significant progress in its clinical efforts for sabirnetug, with faster-than-expected enrollment in the Phase II study.
The company's financial stability, highlighted by $259 million in cash and marketable securities, supports ongoing research and development initiatives.
Challenges in managing R&D expenses and addressing analyst inquiries underscore the complexities and opportunities in advancing Alzheimer's treatments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Charlottesville, VA.

CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the second quarter of 2023 and provided a business update.

Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights

CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease, today announced that the Company will report second quarter financial results on Tuesday, August 8, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023

Two years removed from an IPO, Acumen Pharmaceuticals, Inc. NASDAQ: ABOS looks like it made a good decision to go public. Shares of the Charlottesville, Virginia-based biotechnology company skyrocketed as much as 80% in Monday morning trading after it reported encouraging Alzheimer's disease study results.

Acumen Soars on Alzheimer's Study

CHARLOTTESVILLE, Va. and CARMEL, Ind., July 18, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (“Acumen”) (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced the pricing of an upsized underwritten public offering of 16,774,193 shares of its common stock at a price to the public of $7.75 per share. All of the shares are being offered by Acumen. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Acumen, are expected to be approximately $130 million. The offering is expected to close on July 21, 2023, subject to the satisfaction of customary closing conditions. In addition, Acumen has granted the underwriters a 30-day option to purchase up to an additional 2,516,128 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Acumen Announces Pricing of Upsized $130 Million Public Offering

Acumen's shares rose more than 54% on Monday on positive trial news. Investors were likely taking profits Tuesday.

Why Shares of Acumen Pharmaceuticals Are Down Tuesday

Positive topline results released from phase 1 INTERCEPT-AD study, which used ACU193 for the treatment of patients with early AD. The global market for Alzheimer's disease treatments is expected to rise past $13 billion by 2030. There was statistically significant amyloid plaque reduction observed with higher doses of ACU193 in the phase 1 INTERCEPT-AD study; statistically significant plaque reduction observed with a p-value of p=0.01.

Acumen: A First In Targeting, May Lead To Improvement For Early AD Patients

CHARLOTTESVILLE, Va. and CARMEL, Ind., July 17, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. All of the shares to be sold in the offering are to be sold by Acumen. In connection with the offering, Acumen intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock

Acumen Pharmaceuticals (NASDAQ: ABOS ) stock is on the rise Monday after the company released data from a Phase 1 clinical trial. This data comes from the company's Phase 1 INTERCEPT-AD trial of ACU193.

Why Is Acumen Pharmaceuticals (ABOS) Stock Up 46% Today?

Company to host conference call and webcast for investors and analysts today, July 17, at 8 a.m. ET Company to host conference call and webcast for investors and analysts today, July 17, at 8 a.m. ET

Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's Disease

CHARLOTTESVILLE, Va. and CARMEL, Ind., July 16, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today presented positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage AβO targeting antibody therapy in early AD, at the Alzheimer's Association International Conference (AAIC®) 2023, taking place in Amsterdam and online from July 16-20, 2023.

Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's Disease at the Alzheimer's Association International Conference (AAIC) 2023

An experimental Alzheimer's disease drug developed by Acumen Pharmaceuticals targeting a novel form of the toxic protein beta amyloid in the brain passed an early safety test and will advance to a larger trial, the company said on Sunday.

Acumen's Alzheimer's drug passes initial safety test

CHARLOTTESVILLE, Va. and CARMEL, Ind., June 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that it will present topline results from a Phase 1 trial of its candidate ACU193, the first clinical stage AβO-directed antibody therapy, at the Alzheimer's Association International Conference (AAIC®) 2023 taking place in Amsterdam, Netherlands and online from July 16-20, 2023. As part of a Featured Research Session - Developing Topics platform, four presentations will be made that discuss the Phase 1 trial.

Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's Disease During Featured Research Session at the Alzheimer's Association International Conference (AAIC®) 2023

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants Alex Braun - Head IR Daniel O'Connell - President and CEO Eric Siemers - Chief Medical Officer Matt Zuga - CFO and Chief Business Officer Conference Call Participants Tom Shrader - BTIG Judah Frommer - Credit Suisse Charlie Yang - BofA Operator Good day, and thank you for standing by. Welcome to the Acumen Pharma Q1 2023 Conference Call and Webcast.

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2023 Earnings Call Transcript

CHARLOTTESVILLE, Va. and Carmel, Ind., May 09, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the first quarter of 2023 and provided a business update.

Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights

CHARLOTTESVILLE, Va. and CARMEL, Ind., May 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 2023 Bank of America Healthcare Conference on Thursday, May 11, 2023 at 8:00 a.m. PT (11:00 a.m. ET). The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare Conference

CHARLOTTESVILLE, Va. and CARMEL, Ind., May 02, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease, today announced that the Company will report first quarter financial results on Tuesday, May 9, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 28, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic globular soluble amyloid beta oligomers (sAβOs) for the treatment of Alzheimer's disease (AD), has demonstrated the utility of a human in vitro model of iPSC-derived excitatory neurons for a better understanding of which forms of amyloid beta oligomers contribute to the pathogenesis of AD in the human brain. This research will be presented in a poster at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD), held in-person in Gothenburg, Sweden, and virtually March 28 – April 1, 2023.

Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimer's Disease

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q4 2022 Earnings Conference Call March 27, 2023 8:00 AM ET Company Participants Alex Braun - Head IR Daniel O'Connell - President and Chief Executive Officer Eric Siemers - , Chief Medical Officer Matt Zuga - Chief Financial Officer and Chief Business Office Conference Call Participants Paul Matteis - Stifel Tom Shrader - BTIG Judah Frommer - Credit Suisse Operator Thank you for standing by. Welcome to Acumen Pharmaceuticals Full Year 2022 Conference Call and Webcast.

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2022 Earnings Call Transcript

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 27, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) and is designed for the treatment of Alzheimer's disease (AD), today reported financial results for the full year ended December 31, 2022 and provided a business update.

Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 22, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Stifel 2023 Virtual CNS Days on Wednesday, March 29, 2023 at 12:30 p.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 14 days.

Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 20, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2022 financial results on Monday, March 27, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 08, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Needham Virtual Neuroscience Forum on Wednesday, March 15, 2023 at 10:00 a.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 14 days.

Acumen Pharmaceuticals to Participate in the Needham Neuroscience Forum

Topline results including safety and proof-of-mechanism data expected in third quarter of 2023 Topline results including safety and proof-of-mechanism data expected in third quarter of 2023

Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early Alzheimer's Disease

CHARLOTTESVILLE, Va. and CARMEL, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today announced Derrell Porter, M.D., has joined its Board of Directors.

Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Alex Braun - Head IR Daniel O'Connell - President and CEO Eric Siemers - CMO Matt Zuga - CFO and CBO Conference Call Participants Tom Shrader - BTIG Judah Frommer - Credit Suisse Charlie Yang - Bank of America Operator Good day. Thank you for standing by.

News for Acumen Pharmaceuticals Stock (ABOS)